Surgery following response to interferon-α-based therapy for residual renal cell carcinoma

A. Sella, D. A. Swanson, J. Y. Ro, J. B. Putnam, R. J. Amato, Avi Markowitz, C. J. Logothetis

    Research output: Contribution to journalArticle

    63 Citations (Scopus)

    Abstract

    The role of aggressive surgery for metastatic renal cancer in the era of biological therapy is not clear. Therefore, we reviewed 17 patients who, between February 1987 and August 1990, underwent surgical resection of residual masses following initial response to interferon-α-based therapy. Viable tumor persisted in 15 patients (88%), whereas only inflammatory response was detected in 2. Of the patients 11 (65%) remained disease-free at a median of 12 months postoperatively (range 5 to 29), with an overall median survival of 26 months (range 6 to 34) from treatment initiation. These data suggest that surgery may be of therapeutic benefit in select patients with renal cell carcinoma who do not meet traditional criteria for surgical resection. Prospective trials are being performed to determine whether there is a role for aggressive surgical resection of persistent disease in patients with advanced renal cell carcinoma who have previously responded to interferon-α-based therapy.

    Original languageEnglish (US)
    Pages (from-to)19-22
    Number of pages4
    JournalJournal of Urology
    Volume149
    Issue number1
    StatePublished - 1993

    Fingerprint

    Renal Cell Carcinoma
    Interferons
    Therapeutics
    Biological Therapy
    Kidney Neoplasms
    Survival
    Neoplasms

    Keywords

    • carcinoma, renal cell
    • interferon type I
    • kidney neoplasms

    ASJC Scopus subject areas

    • Urology

    Cite this

    Sella, A., Swanson, D. A., Ro, J. Y., Putnam, J. B., Amato, R. J., Markowitz, A., & Logothetis, C. J. (1993). Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. Journal of Urology, 149(1), 19-22.

    Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. / Sella, A.; Swanson, D. A.; Ro, J. Y.; Putnam, J. B.; Amato, R. J.; Markowitz, Avi; Logothetis, C. J.

    In: Journal of Urology, Vol. 149, No. 1, 1993, p. 19-22.

    Research output: Contribution to journalArticle

    Sella, A, Swanson, DA, Ro, JY, Putnam, JB, Amato, RJ, Markowitz, A & Logothetis, CJ 1993, 'Surgery following response to interferon-α-based therapy for residual renal cell carcinoma', Journal of Urology, vol. 149, no. 1, pp. 19-22.
    Sella A, Swanson DA, Ro JY, Putnam JB, Amato RJ, Markowitz A et al. Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. Journal of Urology. 1993;149(1):19-22.
    Sella, A. ; Swanson, D. A. ; Ro, J. Y. ; Putnam, J. B. ; Amato, R. J. ; Markowitz, Avi ; Logothetis, C. J. / Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. In: Journal of Urology. 1993 ; Vol. 149, No. 1. pp. 19-22.
    @article{737550a73cc249509b811525ffd06c72,
    title = "Surgery following response to interferon-α-based therapy for residual renal cell carcinoma",
    abstract = "The role of aggressive surgery for metastatic renal cancer in the era of biological therapy is not clear. Therefore, we reviewed 17 patients who, between February 1987 and August 1990, underwent surgical resection of residual masses following initial response to interferon-α-based therapy. Viable tumor persisted in 15 patients (88{\%}), whereas only inflammatory response was detected in 2. Of the patients 11 (65{\%}) remained disease-free at a median of 12 months postoperatively (range 5 to 29), with an overall median survival of 26 months (range 6 to 34) from treatment initiation. These data suggest that surgery may be of therapeutic benefit in select patients with renal cell carcinoma who do not meet traditional criteria for surgical resection. Prospective trials are being performed to determine whether there is a role for aggressive surgical resection of persistent disease in patients with advanced renal cell carcinoma who have previously responded to interferon-α-based therapy.",
    keywords = "carcinoma, renal cell, interferon type I, kidney neoplasms",
    author = "A. Sella and Swanson, {D. A.} and Ro, {J. Y.} and Putnam, {J. B.} and Amato, {R. J.} and Avi Markowitz and Logothetis, {C. J.}",
    year = "1993",
    language = "English (US)",
    volume = "149",
    pages = "19--22",
    journal = "Journal of Urology",
    issn = "0022-5347",
    publisher = "Elsevier Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Surgery following response to interferon-α-based therapy for residual renal cell carcinoma

    AU - Sella, A.

    AU - Swanson, D. A.

    AU - Ro, J. Y.

    AU - Putnam, J. B.

    AU - Amato, R. J.

    AU - Markowitz, Avi

    AU - Logothetis, C. J.

    PY - 1993

    Y1 - 1993

    N2 - The role of aggressive surgery for metastatic renal cancer in the era of biological therapy is not clear. Therefore, we reviewed 17 patients who, between February 1987 and August 1990, underwent surgical resection of residual masses following initial response to interferon-α-based therapy. Viable tumor persisted in 15 patients (88%), whereas only inflammatory response was detected in 2. Of the patients 11 (65%) remained disease-free at a median of 12 months postoperatively (range 5 to 29), with an overall median survival of 26 months (range 6 to 34) from treatment initiation. These data suggest that surgery may be of therapeutic benefit in select patients with renal cell carcinoma who do not meet traditional criteria for surgical resection. Prospective trials are being performed to determine whether there is a role for aggressive surgical resection of persistent disease in patients with advanced renal cell carcinoma who have previously responded to interferon-α-based therapy.

    AB - The role of aggressive surgery for metastatic renal cancer in the era of biological therapy is not clear. Therefore, we reviewed 17 patients who, between February 1987 and August 1990, underwent surgical resection of residual masses following initial response to interferon-α-based therapy. Viable tumor persisted in 15 patients (88%), whereas only inflammatory response was detected in 2. Of the patients 11 (65%) remained disease-free at a median of 12 months postoperatively (range 5 to 29), with an overall median survival of 26 months (range 6 to 34) from treatment initiation. These data suggest that surgery may be of therapeutic benefit in select patients with renal cell carcinoma who do not meet traditional criteria for surgical resection. Prospective trials are being performed to determine whether there is a role for aggressive surgical resection of persistent disease in patients with advanced renal cell carcinoma who have previously responded to interferon-α-based therapy.

    KW - carcinoma, renal cell

    KW - interferon type I

    KW - kidney neoplasms

    UR - http://www.scopus.com/inward/record.url?scp=0027465079&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0027465079&partnerID=8YFLogxK

    M3 - Article

    VL - 149

    SP - 19

    EP - 22

    JO - Journal of Urology

    JF - Journal of Urology

    SN - 0022-5347

    IS - 1

    ER -